Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha (Q80559670)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 August 2007

Language	Label	Description	Also known as
English	Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha	scientific article published on 01 August 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

myeloid leukemia

1 reference

based on heuristic

inferred from title

chronic myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Rachel Koelmeyer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Susan Branford

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Timothy Hughes

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Alvin Milner

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Anthony Schwarer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Chris Arthur

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Robin Filshie

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Susan Moreton

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Kevin Lynch

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Kerry Taylor

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

110

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

801-808

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of CML using IFN-alpha: impact on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22842

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22842

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17607681%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80559670&oldid=1754283103"